Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.49 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.47 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2809356 | 0.87 | GRM1 (0.54) | ALDH1A1HPGDTSHRGRM1GRM5 | |
| SCHEMBL6287500 | 0.85 | KDM4E (0.59) | ALDH1A1HPGDTSHRGRM1GRM5 | |
| SCHEMBL30677333 | 0.84 | GRM1 (0.53) | ALDH1A1HPGDTSHRGRM1GRM5 | |
| SCHEMBL2786336 | 0.84 | GRM1 (0.55) | ALDH1A1HPGDGRM1KDM4EKMT2A | |
| SCHEMBL23274461 | 0.84 | ALDH1A1 (0.59) | ALDH1A1HPGDTSHRGRM1GRM5 | |
| SCHEMBL31051085 | 0.84 | SMN1; SMN2 (0.48) | ALDH1A1HPGDTSHRGRM1KDM4E | |
| SCHEMBL20102975 | 0.84 | TYK2 (0.53) | HPGDTSHRGRM1GRM5KMT2A | |
| SCHEMBL26859548 | 0.83 | KDM4E (0.51) | ALDH1A1HPGDTSHRGRM1GRM5 | |
| SCHEMBL2786428 | 0.82 | RXFP1 (0.49) | ALDH1A1TSHRGRM1KDM4ETP53 | |
| SCHEMBL16981667 | 0.81 | ALDH1A1 (0.47) | ALDH1A1TSHRGRM1GRM5KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4719385-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | University of Vermont and State Agricultural College (US) | 2026-04-08 | — | — | EP | disclosed |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | ILDONG PHARMACEUTICAL CO LTD (KR) | 2025-12-25 | — | — | US | disclosed |
| US-20250360134-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES | INST NAT SANTE RECH MED (FR) | 2025-11-27 | — | — | US | disclosed |
| WO-2025215582-A1 | SUBSTITUTED PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE | GT GAIN THERAPEUTICS SA (CH) | 2025-10-16 | — | — | WO | disclosed |
| EP-4556476-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| US-20250145642-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | Kineta, Inc. | 2025-05-08 | — | — | US | disclosed |
| US-12195469-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-01-14 | — | — | US | disclosed |
| US-12187729-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2025-01-07 | — | — | US | disclosed |
| WO-2024249380-A2 | 1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINES AS ANTI-INFECTIOUS AGENTS | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-118946360-A | Bicyclic heteroarenes and methods of use thereof | 奇尼塔公司 | 2024-11-12 | — | — | CN | disclosed |
| US-20040023992-A1 | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-05 | — | — | US | disclosed |
| EP-0390112-B1 | Selective adenosine receptor agents | MERRELL PHARMA INC (US) | 1998-01-28 | — | — | EP | disclosed |
| US-5391739-A | Adenosine antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-02-21 | — | — | US | disclosed |
| EP-0390111-B1 | Selective adenosine receptor compounds | MERRELL DOW PHARMA (US) | 1994-09-14 | — | — | EP | disclosed |
| US-5329007-A | Selective adenosine receptor agents | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-07-12 | — | — | US | disclosed |
| US-5256650-A | Hypotensive, antispasmodic agents; sedatives; vasodilation | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-10-26 | — | — | US | disclosed |
| US-5086176-A | Adenosine antagonist | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-02-04 | — | — | US | disclosed |
| US-5064947-A | Enhance physiological effects while minimizing others such as decreasing blood pressure without decreasing heart rate | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-11-12 | — | — | US | disclosed |
| EP-0390112-A2 | Selective adenosine receptor agents | MERRELL PHARMACEUTICALS INC. (US) | 1990-10-03 | — | — | EP | disclosed |
| EP-0390111-A2 | Selective adenosine receptor compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12187729-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | PDE9A, PDE5A, PDE3A | ALDH1A1 517/4885HPGD 966/4885TSHR 4222/4885 |
| US-12195469-B2 | Compounds having PDE9A inhibitory activity, and pharmaceutical uses thereof | PDE9A, PDE5A, PDE3A | ALDH1A1 517/4885HPGD 966/4885TSHR 4222/4885 |
| US-20040023992-A1 | Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors | MAP4K2, MAP3K19, BRAF | ALDH1A1 1321/4885HPGD 2023/4885TSHR 2343/4885 |
| US-20250360134-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES | SARS1, CCR5, INTS6 | ALDH1A1 3238/4885HPGD 4266/4885TSHR 170/4885 |
| US-20250388582-A1 | NOVEL BICYCLIC HETEROARYL COMPOUND AND USE THEREOF | GBA1, PIKFYVE, MAN2B1 | ALDH1A1 3837/4885HPGD 4458/4885TSHR 3647/4885 |
| US-20250145642-A1 | BICYCLIC HETEROARENES AND METHODS OF THEIR USE | TARDBP, TDP2, PSEN2 | ALDH1A1 2999/4885HPGD 2260/4885TSHR 4389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.